Background
Methods
Search strategy
Inclusion criteria
Qualitative assessment
Assessment parameter | Scale | |||
---|---|---|---|---|
Clincal reports | Prognostic factors | Age | 0 | 2 |
Gender | 0 | 2 | ||
Performance status | 0 | 2 | ||
Tumor characteristics | Location of primary tumor | 0 | 2 | |
Number of metastatic sites | 0 | 2 | ||
Size of hepatic metastasis | 0 | 2 | ||
Differentiation grade | 0 | 2 | ||
Description of the results of survival analysis | Number of patients | 0 | 2 | |
Number of deaths | 0 | 2 | ||
Follow-up duration | 0 | 2 | ||
Number of patients lost to follow-up | 0 | 2 | ||
Univariate and multivariate analyses | 0 | 2 | ||
Description of statistical tests | 0 | 2 | ||
Survival definition | 0 | 2 | ||
SUV cutoff definition or response definition | 0 | 2 | ||
Subscores | ||||
PET/CT reports | Patients’ Characteristics | Weight | 0 | 2 |
Glycaemia | 0 | 2 | ||
18FDG PET acquisition protocol characteristics | Injected dose of 18FDG | 0 | 2 | |
Delay between injection | 0 | 2 | ||
Data acquisition | 0 | 2 | ||
Fasting duration | 0 | 2 | ||
Technical Parameters | SUV formula | 0 | 2 | |
Type of PET/CT engine | 0 | 2 | ||
Type of SUV attenuation and reconstruction parameters | 0 | 2 | ||
Subscores | ||||
Total scores |
Data extraction and analyses
Results
Study inclusion and characteristics analyses
Study | Publication year | Number of patients | Study design | PET/CT timing | Type of treatment | End pointsa
| Methodology score (%) |
---|---|---|---|---|---|---|---|
de Geus-Oei L F et al. | 2006 | 152 | Retrospective | Pretreatment | Resection or Chemotherapy | OS | 83.33 % |
Small RM et al. [21] | 2009 | 54 | retrospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(PFS) | 50.00 % |
Hendlisz A et al. | 2011 | 41 | Prospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(PFS) | 70.83 % |
Muralidharan V et al. | 2012 | 30 | retrospective | Pretreatment | Resection | OS EFS(RFS) | 75.00 % |
De Bruyne S et al. [22] | 2012 | 19 | Retrospective | Pretreatment and posttreatment | Chemotherapy and bevacizumab | EFS(PFS) | 75.00 % |
Lastoria S et al. | 2013 | 33 | Retrospective | Pretreatment and posttreatment | Chemotherapy and Bevacizumab | EFS(PFS) OS | 66.67 % |
Mertens J et al. [23] | 2013 | 18 | Prospective | Pretreatment and posttreatment | Chemotherapy and Bevacizumab | OS | 75.00 % |
Zerizer I et al. | 2013 | 25 | Retrospective | Pretreatment and posttreatment |
90Y radioembolization | EFS(PFS) | 70.83 % |
Fendler W P et al. | 2013 | 80 | Retrospective | Pretreatment and posttreatment |
90Y radioembolization | OS | 62.50 % |
Jones C et al. | 2014 | 79 | retrospective | Pretreatment | Resection | OS | 54.17 % |
Lee HS et al. [24] | 2014 | 120 | retrospectively | Pretreatment | Resection | OS EFS(RFS) | 83.33 % |
Lau LF et al. | 2014 | 37 | retrospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(RFS) | 58.33 % |
Riedl CC et al. [25] | 2007 | 90 | retrospective | Pretreatment | Resection | OS | 54.17 % |
Correa-Gallego C et al. | 2015 | 38 | Prospective | Pretreatment and posttreatment | Chemotherapy and bevacizumab | OS EFS(PFS) | 83.33 % |
Sabet A et al. | 2015 | 51 | retrospective | Pretreatment and posttreatment |
90Y radioembolization | OS | 70.83 % |
study | Type of SUV | Correction of SUV | Threshold definition | SUV threshold |
---|---|---|---|---|
de Geus-Oei L F et al. | preSUVmean | Body weight | Median | >4.26 |
Muralidharan V et al. | preSUVmean | Body weight | Best cut-off | >10 |
De Bruyne S et al. | postSUVmax | Body weight | Median | >2.85 |
Mertens J et al. | postSUVmax | Body weight | Median | 2.85 |
Claire Jones.et al. | PreSUVmean | Body weight | Arbitrary | >7.0 |
Lee HS et al. | PreanSUVpeak | Body weight | Median | >5.0 |
Lau LF et al. | postSUVmax | Body weight | Previous report | >10 |
Riedl CC et al. | preSUVmax | Body weight | Best cut-off | >10 |
Correa-Gallego C et al. | preSUVmax | Body weight | Median | >10 |
Study | Type of SUV | Correction of SUV | Threshold definition | SUV threshold |
---|---|---|---|---|
Small RM et al. |
aΔSUV | Body weight | Visual observation | unclear |
Hendlisz A et al. | ΔSUVmax | Body weight |
bEORTC | metabolic decrease > 25 % |
De Bruyne S et al. | ΔSUVmax | Body weight | EORTC | metabolic decrease > 25 % |
Lastoria S et al. | ΔSUVmax | Body weight | Median | metabolic decrease > 50 % |
Zerizer I et al. | ΔSUVmax | Body weight | Best cut-off | metabolic decrease > 2.0 |
Fendler W P et al. | ΔSUVmax | Body weight |
cPERCIST | metabolic decrease > 30 % |
Correa-Gallego C et al. | ΔSUVmax | Body weight |
dWHO | metabolic decrease > 25 % |
Sabet A et al. | ΔSUV | Body weight | Best cut-off | metabolic decrease > 50 % |